GT Biopharma Shares to Reverse Split on Tuesday, September 8th (NASDAQ:GTBP)

Shares of GT Biopharma, Inc. (NASDAQ:GTBP) are going to reverse split before the market opens on Tuesday, September 8th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 7th.

GT Biopharma Price Performance

Shares of GTBP stock traded down $0.01 during trading hours on Friday, reaching $0.24. The company had a trading volume of 1,158,788 shares, compared to its average volume of 1,121,215. The business has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.39. GT Biopharma has a 12 month low of $0.22 and a 12 month high of $1.37. The company has a market cap of $10.87 million, a price-to-earnings ratio of -0.04 and a beta of 0.91.

GT Biopharma (NASDAQ:GTBP) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). On average, equities research analysts expect that GT Biopharma will post -0.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on GTBP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. Wall Street Zen raised shares of GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. 49 Wealth Management LLC acquired a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned about 0.14% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by institutional investors and hedge funds.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).